At a glance
ClinicalIndex Comparison RecordPhase 3Active· 996 enrolled
Drug / intervention
Mirikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
In Brief
A Phase 3 clinical trial evaluating Mirikizumab for Crohn's Disease. Active but no longer recruiting, targeting 996 participants across 322 sites in 32 countries.
Detailed Summary
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Slovakia, South Korea, Switzerland, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3Active
20202021202220232024202520262027
First PostedJan 2020
Enrollment StartJun 2020
Primary CompletionNov 2024
TodayJul 2026
Study CompletionApr 2027
First PostedJan 18, 2020
Enrollment StartJun 22, 2020
Primary CompletionNov 28, 2024
Study CompletionApr 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.5 years ago
Interventions
Mirikizumabdrug
Administered Q4W